Lack of association between obesity and aggressiveness of differentiated thyroid cancer

Abstract

Purpose

Aim of this study was to evaluate the association between body mass index (BMI) and aggressive features of differentiated thyroid cancer (DTC) in a prospective cohort.

Methods

Patients with DTC were prospectively enrolled at a tertiary referral center and grouped according to their BMI. Aggressive clinic-pathological features were analyzed following the American Thyroid Association Initial Risk Stratification System score.

Results

The cohort was composed of 432 patients: 5 (1.2%) were underweight, 187 (43.3%) normal weight, 154 (35.6%) overweight, 68 (15.7%) grade 1 obese, 11 (2.5%) grade 2 obese and 7 (1.6%) grade 3 obese. No single feature of advanced thyroid cancer was more frequent in obese patients than in others. No significant correlation was found between BMI, primary tumor size (Spearman’s ρ − 0.02; p = 0.71) and ATA Initial Risk Stratification System score (ρ 0.03; p = 0.49), after adjustment for age. According to the multivariate logistic regression analysis, male gender and pre-surgical diagnosis of cancer were significant predictors of cancer with high or intermediate–high recurrence risk according to the ATA system (OR 2.06 and 2.51, respectively), while older age at diagnosis was a protective factor (OR 0.98), and BMI was not a predictor. BMI was a predictor of microscopic extrathyroidal extension only (OR 1.06).

Conclusions

Obesity was not associated with aggressive features in this prospective, European cohort of patients with DTC.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Flegal KM, Kruszon-Moran D, Carroll MD et al (2016) Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315:2284–2291. https://doi.org/10.1001/jama.2016.6458

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Ogden CL, Carroll MD, Lawman HG et al (2016) Trends in obesity prevalence among children and adolescents in the United States, 1988–1994 through 2013–2014. JAMA 315:2292–2299. https://doi.org/10.1001/jama.2016.6361

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Buscemi S, Massenti FM, Vasto S et al (2017) Association of obesity and diabetes with thyroid nodules. Endocrine. https://doi.org/10.1007/s12020-017-1394-2

    Article  PubMed  Google Scholar 

  4. 4.

    Panagiotou G, Komninou D, Anagnostis P et al (2017) Association between lifestyle and anthropometric parameters and thyroid nodule features. Endocrine 56:560–567. https://doi.org/10.1007/s12020-017-1285-6

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Zhao ZG, Guo XG, Ba CX et al (2012) Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res 40:2041–2050. https://doi.org/10.1177/030006051204000601

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Rinaldi S, Lise M, Clavel-Chapelon F et al (2012) Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 131:E1004–E1014. https://doi.org/10.1002/ijc.27601

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Han JM, Kim TY, Jeon MJ et al (2013) Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 168:879–886. https://doi.org/10.1530/eje-13-0065

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Pak K, Shin S, Kim SJ et al (2017) Risk of malignancy in thyroid incidentaloma is not increased in overweight or obese patients, but in young patients. Nutr Cancer 69:580–584. https://doi.org/10.1080/01635581.2017.1299877

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Rotondi M, Castagna MG, Cappelli C et al (2016) Obesity does not modify the risk of differentiated thyroid cancer in a cytological series of thyroid nodules. Eur Thyroid J 5:125–131. https://doi.org/10.1159/000445054

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Lamartina L, Grani G, Durante C, Filetti S (2018) Recent advances in managing differentiated thyroid cancer [version 1; referees: 2 approved]. F1000Res 7:86. https://doi.org/10.12688/f1000research.12811.1

    Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Lamartina L, Cooper DS (2015) Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view. Endocrine 50:67–71. https://doi.org/10.1007/s12020-014-0523-4

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Grani G, Carbotta G, Nesca A et al (2015) A comprehensive score to diagnose Hashimoto’s thyroiditis: a proposal. Endocrine 49:361–365. https://doi.org/10.1007/s12020-014-0441-5

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Bulotta S, Celano M, Costante G, Russo D (2016) Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52:214–221. https://doi.org/10.1007/s12020-015-0830-4

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Cabanillas ME, McFadden DG, Durante C (2016) Thyroid cancer. Lancet 388:2783–2795. https://doi.org/10.1016/s0140-6736(16)30172-6

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Kitahara CM, Platz EA, Freeman LE et al (2011) Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomark Prev 20:464–472. https://doi.org/10.1158/1055-9965.epi-10-1220

    Article  Google Scholar 

  17. 17.

    Shin HY, Jee YH, Cho ER (2017) Body mass index and incidence of thyroid cancer in Korea: the Korean Cancer prevention study-II. J Cancer Res Clin Oncol 143:143–149. https://doi.org/10.1007/s00432-016-2261-x

    Article  PubMed  Google Scholar 

  18. 18.

    Kwon H, Kim M, Choi YM et al (2015) Lack of associations between body mass index and clinical outcomes in patients with papillary thyroid carcinoma. Endocrinol Metab (Seoul) 30:305–311. https://doi.org/10.3803/EnM.2015.30.3.305

    Article  Google Scholar 

  19. 19.

    Paes JE, Hua K, Nagy R et al (2010) The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab 95:4244–4250. https://doi.org/10.1210/jc.2010-0440

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Chung YS, Lee JH, Lee YD (2017) Is body mass index relevant to prognosis of papillary thyroid carcinoma? A clinicopathological cohort study. Surg Today 47:506–512. https://doi.org/10.1007/s00595-016-1417-2

    Article  PubMed  Google Scholar 

  21. 21.

    Kim HJ, Kim NK, Choi JH et al (2013) Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf) 78:134–140. https://doi.org/10.1111/j.1365-2265.2012.04506.x

    Article  Google Scholar 

  22. 22.

    Dieringer P, Klass EM, Caine B, Smith-Gagen J (2015) Associations between body mass and papillary thyroid cancer stage and tumor size: a population-based study. J Cancer Res Clin Oncol 141:93–98. https://doi.org/10.1007/s00432-014-1792-2

    Article  PubMed  Google Scholar 

  23. 23.

    Harari A, Endo B, Nishimoto S et al (2012) Risk of advanced papillary thyroid cancer in obese patients. Arch Surg 147:805–811. https://doi.org/10.1001/archsurg.2012.713

    Article  PubMed  Google Scholar 

  24. 24.

    Yu ST, Chen W, Cai Q et al (2017) Pretreatment BMI is associated with aggressive clinicopathological features of papillary thyroid carcinoma: a multicenter study. Int J Endocrinol 2017:5841942. https://doi.org/10.1155/2017/5841942

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Liu Z, Maimaiti Y, Yu P et al (2015) Correlation between body mass index and clinicopathological features of papillary thyroid microcarcinoma. Int J Clin Exp Med 8:16472–16479

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Wu C, Wang L, Chen W et al (2017) Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer: a retrospective study. Medicine (Baltim) 96:e6202. https://doi.org/10.1097/md.0000000000006202

    Article  Google Scholar 

  27. 27.

    Choi JS, Kim EK, Moon HJ, Kwak JY (2015) Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. Endocrine 48:264–271. https://doi.org/10.1007/s12020-014-0293-z

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Diker-Cohen T, Hirsch D, Shimon I et al (2018) Impact of minimal extra-thyroid extension in differentiated thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2018-00081

    Article  PubMed  Google Scholar 

  29. 29.

    Castagna MG, Forleo R, Maino F et al (2018) Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. J Endocrinol Invest. https://doi.org/10.1007/s40618-018-0854-8

    Article  PubMed  Google Scholar 

  30. 30.

    Lamartina L, Grani G, Arvat E et al (2017) 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. Endocr Relat Cancer 25:L7–L11. https://doi.org/10.1530/ERC-17-0453

    Article  PubMed  Google Scholar 

  31. 31.

    Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27:751–756. https://doi.org/10.1089/thy.2017.0102

    Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Lamartina L, Durante C, Lucisano G et al (2017) Are evidence-based guidelines reflected in clinical practice? an analysis of prospectively collected data of the italian thyroid cancer observatory. Thyroid 27:1490–1497. https://doi.org/10.1089/thy.2017.0299

    Article  PubMed  Google Scholar 

  33. 33.

    Dal Maso L, Panato C, Franceschi S et al (2018) The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998–2012. Eur J Cancer 94:6–15. https://doi.org/10.1016/j.ejca.2018.01.083

    Article  Google Scholar 

Download references

Acknowledgements

The study was supported by the Italian Ministry of Universities and Research (MIUR/PRIN 2015 cod. 2015B7M39T_005), the Fondazione Umberto Di Mario ONLUS and Banca d’Italia.

Author information

Affiliations

Authors

Contributions

GG and LL contributed to this paper as recipients of the PhD program of Biotechnologies and Clinical Medicine of the University of Rome, Sapienza.

Corresponding author

Correspondence to C. Durante.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Thyroid cancer patient data were collected at our site, after obtaining the informed consent of the patients and approval of the local ethics committee.

Data availability

The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Grani, G., Lamartina, L., Montesano, T. et al. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. J Endocrinol Invest 42, 85–90 (2019). https://doi.org/10.1007/s40618-018-0889-x

Download citation

Keywords

  • Obesity
  • Body mass index
  • Thyroid cancer
  • Cancer size
  • Aggressive cancer
  • Advanced stage